Juntian Liu

2.0k total citations
49 papers, 1.6k citations indexed

About

Juntian Liu is a scholar working on Cancer Research, Molecular Biology and Oncology. According to data from OpenAlex, Juntian Liu has authored 49 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Cancer Research, 19 papers in Molecular Biology and 14 papers in Oncology. Recurrent topics in Juntian Liu's work include MicroRNA in disease regulation (9 papers), Cancer-related molecular mechanisms research (9 papers) and Tryptophan and brain disorders (9 papers). Juntian Liu is often cited by papers focused on MicroRNA in disease regulation (9 papers), Cancer-related molecular mechanisms research (9 papers) and Tryptophan and brain disorders (9 papers). Juntian Liu collaborates with scholars based in China and United States. Juntian Liu's co-authors include Fangxuan Li, Shixia Li, Xiubao Ren, Jinpu Yu, Hui Li, Shui Cao, Wenwen Yu, Yan Fang, Chun Shen and Yue Wang and has published in prestigious journals such as SHILAP Revista de lepidopterología, The Journal of Immunology and PLoS ONE.

In The Last Decade

Juntian Liu

48 papers receiving 1.6k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Juntian Liu China 21 658 606 507 393 245 49 1.6k
Mary Nesline United States 19 261 0.4× 503 0.8× 414 0.8× 261 0.7× 51 0.2× 73 1.1k
Wuzhen Chen China 19 372 0.6× 396 0.7× 602 1.2× 421 1.1× 14 0.1× 37 1.3k
Pedro Veliça United Kingdom 17 531 0.8× 410 0.7× 588 1.2× 413 1.1× 17 0.1× 23 1.4k
Rongzhang Dou China 18 536 0.8× 588 1.0× 964 1.9× 730 1.9× 12 0.0× 28 1.7k
Andrew Walding United Kingdom 15 133 0.2× 567 0.9× 250 0.5× 110 0.3× 42 0.2× 32 1.1k
Hao‐Wei Teng Taiwan 21 154 0.2× 788 1.3× 576 1.1× 270 0.7× 16 0.1× 73 1.4k
Wentao Zhang China 21 132 0.2× 271 0.4× 629 1.2× 430 1.1× 27 0.1× 81 1.2k
Chunmei Piao China 20 407 0.6× 235 0.4× 483 1.0× 156 0.4× 13 0.1× 41 1.3k
Junfeng Zhang China 21 116 0.2× 346 0.6× 687 1.4× 592 1.5× 25 0.1× 51 1.3k
Jun Qian China 19 122 0.2× 216 0.4× 1.1k 2.2× 936 2.4× 30 0.1× 45 1.7k

Countries citing papers authored by Juntian Liu

Since Specialization
Citations

This map shows the geographic impact of Juntian Liu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Juntian Liu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Juntian Liu more than expected).

Fields of papers citing papers by Juntian Liu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Juntian Liu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Juntian Liu. The network helps show where Juntian Liu may publish in the future.

Co-authorship network of co-authors of Juntian Liu

This figure shows the co-authorship network connecting the top 25 collaborators of Juntian Liu. A scholar is included among the top collaborators of Juntian Liu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Juntian Liu. Juntian Liu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Li, Fangxuan, et al.. (2024). Biomarkers of lipid metabolism in gastric cancer: a case control study. BMC Cancer. 24(1). 455–455. 4 indexed citations
2.
Li, Lijuan, Nan Wu, Lin Geng, et al.. (2023). Heterogeneity and potential therapeutic insights for triple-negative breast cancer based on metabolic‐associated molecular subtypes and genomic mutations. Frontiers in Pharmacology. 14. 1224828–1224828. 3 indexed citations
3.
Yang, Mengmeng, Xiaoyan Wang, Huan Zhang, et al.. (2022). Identification of Three Circulating MicroRNAs in Plasma as Clinical Biomarkers for Breast Cancer Detection. Journal of Clinical Medicine. 12(1). 322–322. 7 indexed citations
4.
Li, Menghui, Lijuan Wei, Fangxuan Li, et al.. (2021). High Risk Thyroid Nodule Discrimination and Management by Modified TI-RADS. Cancer Management and Research. Volume 13. 225–234. 1 indexed citations
5.
Li, Fangxuan, et al.. (2019). CD4/CD8 + T cells, DC subsets, Foxp3, and IDO expression are predictive indictors of gastric cancer prognosis. Cancer Medicine. 8(17). 7330–7344. 101 indexed citations
6.
Li, Fangxuan, et al.. (2019). Multivariate analysis of clinicopathological and prognostic significance of miRNA 106b~25 cluster in gastric cancer. Cancer Cell International. 19(1). 200–200. 5 indexed citations
7.
Liang, Xiaofeng, et al.. (2018). Ultrasound features of extranodal extension in the metastatic cervical lymph nodes of papillary thyroid cancer: a case-control study. Cancer Biology and Medicine. 15(2). 171–171. 7 indexed citations
8.
Li, Fangxuan, Hui Du, Shixia Li, & Juntian Liu. (2018). The Association Between Metabolic Syndrome and Gastric Cancer in Chinese. Frontiers in Oncology. 8. 326–326. 51 indexed citations
9.
Li, Menghui & Juntian Liu. (2018). [Screening of benign and malignant thyroid nodules in 5 196 physical examination population].. PubMed. 40(2). 151–154. 4 indexed citations
10.
Li, Fangxuan, et al.. (2017). The significance of elevated plasma expression of microRNA 106b~25 clusters in gastric cancer. PLoS ONE. 12(5). e0178427–e0178427. 22 indexed citations
11.
Li, Fangxuan, Rupeng Zhang, Shixia Li, & Juntian Liu. (2017). IDO1: An important immunotherapy target in cancer treatment. International Immunopharmacology. 47. 70–77. 119 indexed citations
12.
Zhu, Yanrong, Shouyin Di, Wei Hu, et al.. (2016). A new flavonoid glycoside (APG) isolated from Clematis tangutica attenuates myocardial ischemia/reperfusion injury via activating PKCε signaling. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease. 1863(3). 701–711. 29 indexed citations
13.
Zhang, Rupeng, Fangxuan Li, Weijia Wang, et al.. (2016). The effect of antisense inhibitor of miRNA 106b∼25 on the proliferation, invasion, migration, and apoptosis of gastric cancer cell. Tumor Biology. 37(8). 10507–10515. 24 indexed citations
14.
Li, Fangxuan, Shixia Li, Hui Li, et al.. (2014). The subsets of dendritic cells and memory T cells correspond to indoleamine 2,3-dioxygenase in stomach tumor microenvironment. Tumor Biology. 35(9). 8691–8698. 15 indexed citations
15.
Zhang, Rupeng, Weijia Wang, Fangxuan Li, Hui Zhang, & Juntian Liu. (2014). MicroRNA-106b~25 expressions in tumor tissues and plasma of patients with gastric cancers. Medical Oncology. 31(10). 243–243. 39 indexed citations
16.
Guo, Fengli, et al.. (2013). Signet ring cell carcinoma of the breast: report of 17 cases. Zhonghua putong waike zazhi. 28(1). 39–41. 1 indexed citations
17.
18.
Yang, Baohong, Jinpu Yu, Hui Li, et al.. (2012). Immunosuppressive impact of IDO on T cells in MDSCs of breast cancer. Clinical Oncology and Cancer Research. 39(9). 506–509. 1 indexed citations
19.
Sun, Jingyan, Jinpu Yu, Hui Li, et al.. (2011). Upregulated expression of indoleamine 2, 3-dioxygenase in CHO cells induces apoptosis of competent T cells and increases proportion of Treg cells. Journal of Experimental & Clinical Cancer Research. 30(1). 82–82. 30 indexed citations
20.
Ji, Yuanyuan, et al.. (2007). [Study on anti-atherosclerotic mechanisms of divided functional recipes of dahuang zhechong pill in rabbits].. PubMed. 32(11). 1077–81. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Mary Nesline Breakdown of academic impact, for papers by Wuzhen Chen Breakdown of academic impact, for papers by Pedro Veliça Breakdown of academic impact, for papers by Rongzhang Dou Breakdown of academic impact, for papers by Andrew Walding Breakdown of academic impact, for papers by Hao‐Wei Teng Breakdown of academic impact, for papers by Wentao Zhang Breakdown of academic impact, for papers by Chunmei Piao Breakdown of academic impact, for papers by Junfeng Zhang Breakdown of academic impact, for papers by Jun Qian
Rankless by CCL
2026